On this page
How should human bioanalytical method reports connect to clinical studies?
Map each study to the method version, analyte, matrix, validation evidence and final sample-analysis report supporting its concentrations. Shared method and validation information can be referenced across studies; study-specific analysis remains traceable. Apply M10 only within its scope and preserve investigations, amendments and analytical limitations.
Before you begin
Bioanalytical and analytical evidence supporting human studies. M10 scope and assay-specific provisions need confirmation; biomarker or immunogenicity assays are not automatically the same task.
What you will prepare: A method-to-study map and reviewable report package with resolved validation, version and sample-handling questions.
Identify which document the reviewer needs
Separate the method description, validation report and bioanalytical report for the actual study samples. M4E allows a method and validation used across studies to be provided once in 5.3.1.4 and referenced from those reports. That avoids inconsistent copied method sections; it does not eliminate the study-specific analysis record.
Collect method identifiers and revisions, analytes and matrices, validation and amendment reports, laboratory/site identifiers, sample-analysis dates, processing records and the clinical studies that depend on the results. Establish whether the assay falls within M10's scope before applying its detailed expectations. An assay measuring a drug concentration and one measuring a biological response may need different evidence.
Build the method history around actual changes
Use an internal map with method code, effective revision, assay type, analyte/matrix, validation reference, study report reference and reason for change. M10 section VIII asks for traceability across method, validation and bioanalytical report codes, including relevant partial and cross validations.
Explain why a change was made and the evidence supporting continued use. Examples include a new laboratory, matrix, analytical range or procedure. Have the analytical scientist establish the necessary validation scope; the writer should not declare a change minor based on a familiar method name. Keep unresolved validation coverage visible until that assessment is documented.
Report the evidence behind accepted concentrations
Describe sample receipt and storage, relevant stability coverage, analytical runs, calibration and quality controls, repeats or reintegration, and deviations affecting results. Use M10 Table 1 to distinguish what belongs in the submitted validation report, bioanalytical report and retained laboratory documentation. Comparative BA/BE studies have additional documentation considerations; check the relevant table cells rather than reusing a generic package.
Fictional exercise: samples were stored longer than the stability interval supported by the referenced validation. Record the affected samples and dates, ask the laboratory for the assessment or additional supporting evidence, and identify the consequences for the clinical analysis. A statement that the assay was “validated” does not answer this specific stability question.
Close the connection to clinical interpretation
Check that the concentration dataset used by pharmacokinetics matches the final analytical output, including analyte names, units, sample identifiers and replacement values. Reconcile any report amendment with downstream analyses; changing the method report does not automatically update the PK results.
Provide precise references from each dependent study to the relevant method and validation version. The final review should establish which evidence supports each study, where exceptions remain and who assessed their impact. Do not treat analytical validation as proof that a clinical endpoint, study design or regulatory conclusion is valid.
Map method changes to the clinical analyses they affect
Use the following working record when a laboratory issues a revision. Track what changed before deciding which clinical outputs need attention.
| Change record | Affected scope | Downstream check |
|---|---|---|
| Method or laboratory change | Version, site, analyte and matrix | Appropriate validation or comparison evidence exists |
| Sample-handling issue | Identified samples and dates | Stability or other suitability assessment covers actual conditions |
| Analytical correction | Replaced results and documented reason | Final concentration dataset contains the intended values |
| Clinical recalculation | Parameters and analysis version | Report and summary use the corrected output |
Handoff exercise: the laboratory corrects a concentration unit in an issued table. Determine whether the underlying dataset was also wrong or only the display label differed. The remedies are different. Obtain the documented analytical resolution and have the PK owner assess the affected calculations; do not apply a blanket conversion without identifying the authoritative values.
Reference the resulting method history from the human PK report and any comparative BA/BE report using it. A method can be shared while its sample-specific exceptions differ.
Your preparation checklist
0/4 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Can one validation report support several clinical studies?
M4E permits common method and validation information to be provided once and referenced. Each study still needs a traceable connection to the applicable version and intended use, together with its actual sample-analysis record. Shared documentation does not erase study-specific deviations or limitations.
Does a validated assay cover any sample storage duration?
No. Match the actual sample history to the relevant stability evidence and documented assessment. If storage extends beyond the demonstrated conditions, identify the affected samples and obtain the laboratory’s resolution. A general statement that the method was validated does not answer that specific question.
Does M10 apply to every biomarker or immunogenicity assay?
No. M10 excludes biomarker bioanalysis and methods used to assess immunogenicity. Establish the measured quantity and intended purpose before choosing the validation framework. A shared assay technology does not make all measurements subject to the same guidance.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Guidance
FDA M4E(R2): The CTD: Efficacy ↗July 2017, Revision 1, final. Module 5, printed pp.56–64. Organization guidance, not a list of studies required for every application. Reopened September 22, 2026.
Guidance
FDA M10: Bioanalytical Method Validation and Study Sample Analysis ↗November 2022 final. Scope and section VIII, including Table 1 documentation distinctions. Reopened September 22, 2026.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 5.3.1.4. A heading identifies placement, not mandatory applicability.